CoChat
Sign Up
Cited by 20Alzheimer's disease research and treatmentsMitochondrial Function and PathologyDementia and Cognitive Impairment Research

Sweet Mitochondria: A Shortcut to Alzheimer’s Disease

Open access
Moreira, Paula I.·2018·Journal of Alzheimer’s Disease
DOI 10.3233/jad-170931PMC PMC5869999
Open this paper in CoChat — free accountOpen PDF

Abstract

A growing body of evidence supports a clear association between Alzheimer’s disease and diabetes and several mechanistic links have been revealed. This paper is mainly devoted to the discussion of the role of diabetes-associated mitochondrial defects in the pathogenesis of Alzheimer’s disease. The research experience and views of the author on this subject will be highlighted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-170931

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Compelling evidence links neurodegeneration to altered brain metabolism and mitochondrial dysfunction, both of which are early hallmarks of Alzheimer's disease.

    “Compelling evidence links neurodegeneration to altered brain metabolism and mitochondrial dysfunction, both of which are early hallmarks of AD [21–28].”

    From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [25]

    The Introduction describes metabolic defects as characteristic of sporadic AD, and Author Views and Conclusions links defective brain glucose metabolism and mitochondrial anomalies to AD and neurodegeneration. That section also says mitochondrial defects seem to play an early role in AD development, but our copy does not establish that altered brain metabolism is likewise an early hallmark. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 114

  1. [1]Mattson MP, Gleichmann M, Cheng A (2008) Mitochondria in neuroplasticity and neurological disorders. Neuron 60, 748– 766. 19081372 PMC2692277
  2. [2]Fontán-Lozano A, López-Lluch G, Delgado-García JM, Navas P, Carrión AM (2008) Molecular bases of caloric restriction regulation of neuronal synaptic plasticity. Mol Neurobiol 38, 167– 177. 18759009
  3. [3]Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G (2010) Mitochondrial dysfunction is a trigger of Alzheimer’s disease pathophysiology. Biochim Biophys Acta 1802, 2– 10. 19853658
  4. [4]Correia SC, Perry G, Moreira PI (2016) Mitochondrial traffic jams in Alzheimer’s disease-pinpointing the roadblocks. Biochim Biophys Acta 1862, 1909– 1917. 27460705
  5. [5]Cardoso S, Carvalho C, Correia SC, Seiça RM, Moreira PI (2016) Alzheimer’s disease: From mitochondrial perturbations to mitochondrial medicine. Brain Pathol 26, 632– 647. 27327899 PMC8028979
  6. [6]Cardoso S, Seiça RM, Moreira PI (2017) Mitochondria as a target for neuroprotection: Implications for Alzheimer's disease. Expert Rev Neurother 17, 77– 91. 27366815
  7. [7]Cardoso SM, Correia SC, Carvalho C, Moreira PI (2017) Mitochondria in Alzheimer’s disease and diabetes-associated neurodegeneration: License to heal!. Handb Exp Pharmacol 240, 281– 308. 28251365
  8. [9]Forbes JM, Cooper ME (2013) Mechanisms of diabetic complications. Physiol Rev 93, 137– 188. 23303908
  9. [10]Biessels GJ, Kappelle AC, Bravenboer B, Erkelens DW, Gispen WH (1994) Cerebral function in diabetes mellitus. Diabetologia 37, 643– 650. 7958534
  10. [11]Fried PJ, Schilberg L, Brem AK, Saxena S, Wong B, Cypess AM, Horton ES, Pascual-Leone A (2017) Humans with Type-2 diabetes show abnormal long-term potentiation-like cortical plasticity associated with verbal learning deficits. J Alzheimers Dis 55, 89– 100. 27636847 PMC5193103
  11. [13]van Duinkerken E, Schoonheim MM, Steenwijk MD, Klein M, IJzerman RG, Moll AC, Heymans MW, Snoek FJ, Barkhof F, Diamant M (2014) Ventral striatum, but not cortical volume loss, is related to cognitive dysfunction in type 1 diabetic patients with and without microangiopathy. Diabetes Care 37, 2483– 2490. 24973436
  12. [14]Nunley KA, Rosano C, Ryan CM, Jennings JR, Aizenstein HJ, Zgibor JC, Costacou T, Boudreau RM, Miller R, Orchard TJ, Saxton JA (2015) Clinically relevant cognitive impairment in middle-aged adults with childhood-onset type 1 diabetes. Diabetes Care 38, 1768– 1776. 26153270 PMC4542271
  13. [15]Macpherson H, Formica M, Harris E, Daly RM (2017) Brain functional alterations in Type 2 Diabetes - A systematic review of fMRI studies. Front Neuroendocrinol 47, 34– 46. 28687473
  14. [16]Simó R, Ciudin A, Simó-Servat O, Hernández C (2017) Cognitive impairment and dementia: A new emerging complication of type 2 diabetes - The diabetologist’s perspective. Acta Diabetol 54, 417– 424. 28210868
  15. [17]Smolina K, Wotton CJ, Goldacre MJ (2015) Risk of dementia in patients hospitalised with type 1 and type 2 diabetes in England, 1998-2011: A retrospective national record linkage cohort study. Diabetologia 58, 942– 950. 25673256
  16. [18]Ristow M (2004) Neurodegenerative disorders associated with diabetes mellitus. J Mol Med (Berl) 82, 510– 529. 15175861
  17. [20]Aviles-Olmos I, Limousin P, Lees A, Foltynie T (2013) Parkinson’s disease, insulin resistance and novel agents of neuroprotection. Brain 136, 374– 384. 22344583
  18. [21]Lalić NM, Marić J, Svetel M, Jotić A, Stefanova E, Lalić K, Dragasević N, Milicić T, Lukić L, Kostić VS (2008) Glucose homeostasis in Huntington disease: Abnormalities in insulin sensitivity and early-phase insulin secretion. Arch Neurol 65, 476– 480. 18413469
  19. [22]Moreira PI (2012) Alzheimer’s disease and diabetes: An integrative view of the role of mitochondria, oxidative stress, and insulin. J Alzheimers Dis 30, S199– 215. 22269163
  20. [23]Moreira PI, Santos MS, Seiça R, Oliveira CR (2007) Brain mitochondrial dysfunction as a link between Alzheimer’s disease and diabetes. J Neurol Sci 257, 206– 214. 17316694
  21. [26]Ryan CM, Geckle MO, Orchard TJ (2003) Cognitive efficiency declines over time in adults with Type 1 diabetes: Effects of micro- and macrovascular complications. Diabetologia 46, 940– 948. 12819900
  22. [28]Perantie DC, Lim A, Wu J, Weaver P, Warren SL, Sadler M, White NH, Hershey T (2008) Effects of prior hypoglycemia and hyperglycemia on cognition in children with type 1 diabetes mellitus. Pediatric Diabetes 9, 87– 95. 18208449
  23. [30]Manschot SM, Brands AM, van der Grond J, Kessels RP, Algra A, Kappelle LJ, Biessels GJ, Utrecht Diabetic Encephalopathy Study Group (2006) Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 55, 1106– 1113. 16567535
  24. [31]Ebady SA, Arami MA, Shafigh MH (2009) Investigation on the relationship between diabetes mellitus type 2 and cognitive impairment. Diabetes Res Clin Pract 82, 305– 309. 18848366
  25. [32]van den Berg E, Kloppenborg RP, Kessels RP, Kappelle LJ, Biessels GJ (2009) Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: A systematic comparison of their impact on cognition. Biochim Biophys Acta 1792, 470– 481. 18848880
  26. [33]Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol 5, 64– 74. 16361024
  27. [34]Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM (1996) Association of diabetes mellitus and dementia: The Rotterdam Study. Diabetologia 39, 1392– 1397. 8933010
  28. [35]Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53, 1937– 1942. 10599761
  29. [36]Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, Sulkava R, Kivipelto M (2010) Diabetes, Alzheimer disease, and vascular dementia: A population-based neuropathologic study. Neurology 75, 1195– 1202. 20739645
  30. [37]Cheng D, Noble J, Tang MX, Schupf N, Mayeux R, Luchsinger JA (2011) Type 2 diabetes and late-onset Alzheimer’s disease. Dement Geriatr Cogn Disord 31, 424– 430. 21757907 PMC3142096
  31. [38]Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB, Launer LJ (2008) Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: The Cardiovascular Health Study Cognition Study. Arch Neurol 65, 89– 93. 18195144 PMC11070951
  32. [39]Rastas S, Pirttilä T, Mattila K, Verkkoniemi A, Juva K, Niinistö L, Länsimies E, Sulkava R (2010) Vascular risk factors and dementia in the general population aged >85 years: Prospective population-based study. Neurobiol Aging 31, 1– 7. 18378359
  33. [40]Schnaider Beeri M, Goldbourt U, Silverman JM, Noy S, Schmeidler J, Ravona-Springer R, Sverdlick A, Davidson M (2004) Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 63, 1902– 1907. 15557509
  34. [41]Hitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64, 277– 281. 15668425
  35. [42]Xu W, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L (2009) Mid- and late-life diabetes in relation to the risk of dementia: A population-based twin study. Diabetes 58, 71– 77. 18952836 PMC2606895
  36. [44]Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53, 474– 481. 14747300
  37. [45]Hassing LB, Johansson B, Nilsson SE, Berg S, Pedersen NL, Gatz M, McClearn G (2002) Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer’s disease: A population-based study of the oldest old. Int Psychogeriatr 14, 239– 248. 12475085
  38. [47]Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, Wolf PA, Seshadri S (2006) Diabetes mellitus and risk of developing Alzheimer disease: Results from the Framingham Study. Arch Neurol 63, 1551– 1555. 17101823
  39. [48]Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70, 440– 448. 17942819
  40. [49]Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol 69, 29– 38. 21911655 PMC3260944
  41. [50]Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S (2015) Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease dementia. J Alzheimers Dis 44, 897– 906. 25374101
  42. [51]Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype. Neurobiol Aging 27, 451– 458. 15964100
  43. [52]Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B (2014) Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis 41, 61– 68. 24577463
  44. [53]Moreira PI (2014) Metformin in the diabetic brain: Friend or foe? Ann Transl Med 2, 54. 25333029 PMC4200667
  45. [54]Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, Dixon IJ, Hallett WA, Whitcher B, Brown AP, Zvartau-Hind M, Lotay N, Lai RY, Castiglia M, Jeter B, Matthews JC, Chen K, Bandy D, Reiman EM, Gold M, Rabiner EA, Matthews PM (2006) A multi-center randomized proof-of-concept clinical trial applying [18F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer’s disease. J Alzheimers Dis 22, 1241– 1256. 20930300
  46. [55]Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD, Rosiglitazone in Alzheimer’s Disease Study Group (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J 6, 246– 254. 16446752
  47. [56]Liu J, Wang LN, Jia JP (2015) Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer’s disease and amnestic mild cognitive impairment: A systematic review and meta-analysis. Drugs Aging 32, 57– 65. 25504005
  48. [57]Lu CH, Yang CY, Li CY, Hsieh CY, Ou HT (2017) Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: A population-based longitudinal study. Diabetologia. doi: 10.1007/s00125-017-4499-5 29138876 · DOI
  49. [58]Isik AT, Soysal P, Yay A, Usarel C (2017) The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer’s disease. Diabetes Res Clin Pract 123, 192– 198. 28056430
  50. [59]Gejl M, Gjedde A, Egefjord L, Møller A, Hansen SB, Vang K, Rodell A, Brændgaard H, Gottrup H, Schacht A, Møller N, Brock B, Rungby J (2016) In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci 8, 108. 27252647 PMC4877513
  51. [60]Sebastião I, Candeias E, Santos MS, de Oliveira CR, Moreira PI, Duarte AI (2014) Insulin as a bridge between type 2 diabetes and Alzheimer disease - how anti-diabetics could be a solution for dementia. Front Endocrinol (Lausanne) 5, 110. 25071725 PMC4086025
  52. [61]Moreira PI, Santos MS, Sena C, Seiça R, Oliveira CR (2005) Insulin protects against amyloid beta-peptide toxicity in brain mitochondria of diabetic rats. Neurobiol Dis 18, 628– 637. 15755688
  53. [62]De Felice FG, Ferreira ST (2014) Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63, 2262– 2272. 24931033
  54. [63]Wang Y, Wu L, Li J, Fang D, Zhong C, Chen JX, Yan SS (2015) Synergistic exacerbation of mitochondrial and synaptic dysfunction and resultant learning and memory deficit in a mouse model of diabetic Alzheimer’s disease. J Alzheimers Dis 43, 451– 463. 25096625 PMC4466096
  55. [64]Mastrocola R, Restivo F, Vercellinatto I, Danni O, Brignardello E, Aragno M, Boccuzzi G (2005) Oxidative and nitrosative stress in brain mitochondria of diabetic rats. J Endocrinol 187, 37– 44. 16214939
  56. [65]Zhou Y, Luo Y, Dai J (2013) Axonal and dendritic changes are associated with diabetic encephalopathy in rats: An important risk factor for Alzheimer’s disease. J Alzheimers Dis 34, 937– 947. 23302655
  57. [66]Solanki I, Parihar P, Shetty R, Parihar MS (2017) Synaptosomal and mitochondrial oxidative damage followed by behavioral impairments in streptozotocin induced diabetes mellitus: Restoration by Malvastrum tricuspidatum. Cell Mol Biol (Noisy-le-grand) 63, 94– 101. 28838347
  58. [67]Qu Z, Jiao Z, Sun X, Zhao Y, Ren J, Xu G (2011) Effects of streptozotocin-induced diabetes on tau phosphorylation in the rat brain. Brain Res 1383, 300– 306. 21281610
  59. [68]Kim DY, Jung SY, Kim TW, Lee KS, Kim K (2015) Treadmill exercise decreases incidence of Alzheimer’s disease by suppressing glycogen synthase kinase-3β expression in streptozotocin-induced diabetic rats. J Exerc Rehabil 11, 87– 94. 25960981 PMC4415755
  60. [69]Currais A, Prior M, Lo D, Jolivalt C, Schubert D, Maher P (2012) Diabetes exacerbates amyloid and neurovascular pathology in aging-accelerated mice. Aging Cell 11, 1017– 1026. 22938075 PMC3500443
  61. [70]Liu LP, Yan TH, Jiang LY, Hu W, Hu M, Wang C, Zhang Q, Long Y, Wang JQ, Li YQ, Hu M, Hong H (2013) Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain β-amyloid through PPARγ activation. Acta Pharmacol Sin 34, 455– 463. 23524568 PMC4002797
  62. [71]Zou W, Yuan J, Tang ZJ, Wei HJ, Zhu WW, Zhang P, Gu HF, Wang CY, Tang XQ (2017) Hydrogen sulfide ameliorates cognitive dysfunction in streptozotocin-induced diabetic rats: Involving suppression in hippocampal endoplasmic reticulum stress. Oncotarget 8, 64203– 64216. 28969063 PMC5609995
  63. [72]Zheng H, Lin Q, Wang D, Xu P, Zhao L, Hu W, Bai G, Yan Z, Gao H (2017) NMR-based metabolomics reveals brain region-specific metabolic alterations in streptozotocin-induced diabetic rats with cognitive dysfunction. Metab Brain Dis 32, 585– 593. 28070703
  64. [75]Schultes B, Kern W, Oltmanns K, Peters A, Gais S, Fehm HL, Born J (2005) Differential adaptation of neurocognitive brain functions to recurrent hypoglycemia in healthy men. Psychoneuroendocrinology 30, 149– 161. 15471613
  65. [76]Cardoso S, Correia SC, Santos RX, Carvalho C, Candeias E, Duarte AI, Plácido AI, Santos MS, Moreira PI (2013) Hyperglycemia, hypoglycemia and dementia: Role of mitochondria and uncoupling proteins. Curr Mol Med 13, 586– 601. 22934852
  66. [77]McGowan JE, Chen L, Gao D, Trush M, Wei C (2006) Increased mitochondrial reactive oxygen species production in newborn brain during hypoglycemia. Neurosci Lett 399, 111– 114. 16490311
  67. [78]Pelligrino DA, Becker GL, Miletich DJ, Albrecht RF (1989) Cerebral mitochondrial respiration in diabetic and chronically hypoglycemic rats. Brain Res 479, 241– 246. 2522340
  68. [79]Cardoso S, Santos MS, Seiça R, Moreira PI (2010) Cortical and hippocampal mitochondria bioenergetics and oxidative status during hyperglycemia and/or insulin-induced hypoglycemia. Biochim Biophys Acta 1802, 942– 951. 20620209
  69. [80]Cardoso S, Carvalho C, Santos R, Correia S, Santos MS, Seiça R, Oliveira CR, Moreira PI (2011) Impact of STZ-induced hyperglycemia and insulin-induced hypoglycemia in plasma amino acids and cortical synaptosomal neurotransmitters. Synapse 65, 457– 466. 20853444
  70. [81]Cardoso S, Santos RX, Correia SC, Carvalho C, Santos MS, Baldeiras I, Oliveira CR, Moreira PI (2013) Insulin-induced recurrent hypoglycemia exacerbates diabetic brain mitochondrial dysfunction and oxidative imbalance. Neurobiol Dis 49, 1– 12. 22940631
  71. [82]Dave KR, Tamariz J, Desai KM, Brand FJ, Liu A, Saul I, Bhattacharya SK, Pileggi A (2011) Recurrent hypoglycemia exacerbates cerebral ischemic damage in streptozotocin-induced diabetic rats. Stroke 42, 1404– 1411. 21454816
  72. [83]Bechmann I, Diano S, Warden CH, Bartfai T, Nitsch R, Horvath TL (2002) Brain mitochondrial uncoupling protein 2 (UCP2): A protective stress signal in neuronal injury. Biochem Pharmacol 64, 363– 367. 12147286
  73. [84]Cardoso S, Correia S, Carvalho C, Candeias E, Plácido AI, Duarte AI, Seiça RM, Moreira PI (2015) Perspectives on mitochondrial uncoupling proteins-mediated neuroprotection. J Bioenerg Biomembr 47, 119– 131. 25217852
  74. [85]Cardoso S, Santos MS, Moreno A, Moreira PI (2013) UCP2 and ANT differently modulate proton-leak in brain mitochondria of long-term hyperglycemic and recurrent hypoglycemic rats. J Bioenerg Biomembr 45, 397– 407. 23504111
  75. [86]Cardoso S, Seiça RM, Moreira PI (2018) Uncoupling protein 2 inhibition exacerbates glucose fluctuation-mediated neuronal effects. Neurotox Res 33, 388– 401. 28875237
  76. [87]Rudofsky G Jr, Schroedter A, Schlotterer A, Voron’ko OE, Schlimme M, Tafel J, Isermann BH, Humpert PM, Morcos M, Bierhaus A, Nawroth PP, Hamann A (2006) Functional polymorphisms of UCP2 and UCP3 are associated with a reduced prevalence of diabetic neuropathy in patients with type 1 diabetes. Diabetes Care 29, 89– 94. 16373902
  77. [88]Raza H, John A, Howarth FC (2015) Increased oxidative stress and mitochondrial dysfunction in zucker diabetic rat liver and brain. Cell Physiol Biochem 35, 1241– 1251. 25766534
  78. [89]Carvalho C, Correia SC, Santos MS, Baldeiras I, Oliveira CR, Seica R, Moreira PI (2014) Vascular, oxidative, and synaptosomal abnormalities during aging and the progression of type 2 diabetes. Curr Neurovasc Res 11, 330– 339. 25182811
  79. [90]Carvalho C, Cardoso S, Correia SC, Santos RX, Santos MS, Baldeiras I, Oliveira CR, Moreira PI (2012) Metabolic alterations induced by sucrose intake and Alzheimer’s disease promote similar brain mitochondrial abnormalities. Diabetes 61, 1234– 1242. 22427376 PMC3331754
  80. [91]Carvalho C, Machado N, Mota PC, Correia SC, Cardoso S, Santos RX, Santos MS, Oliveira CR, Moreira PI (2013) Type 2 diabetic and Alzheimer’s disease mice present similar behavioral, cognitive, and vascular anomalies. J Alzheimers Dis 35, 623– 635. 23478310
  81. [93]Sena CM, Pereira AM, Carvalho C, Fernandes R, Seiça RM, Oliveira CR, Moreira PI (2015) Type 2 diabetes aggravates Alzheimer’s disease-associated vascular alterations of the aorta in mice. J Alzheimers Dis 45, 127– 138. 25471187
  82. [94]Huang S, Wang Y, Gan X, Fang D, Zhong C, Wu L, Hu G, Sosunov AA, McKhann GM, Yu H, Yan SS (2015) Drp1-mediated mitochondrial abnormalities link to synaptic injury in diabetes model. Diabetes 64, 1728– 1742. 25412623 PMC4407851
  83. [95]Akhtar MW, Sanz-Blasco S, Dolatabadi N, Parker J, Chon K, Lee MS, Soussou W, McKercher SR, Ambasudhan R, Nakamura T, Lipton SA (2016) Elevated glucose and oligomeric β-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation. Nat Commun 7, 10242. 26743041 PMC4729876
  84. [97]Pintana H, Apaijai N, Chattipakorn N, Chattipakorn SC (2013) DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. J Endocrinol 218, 1– 11. 23591914
  85. [98]Pintana H, Apaijai N, Pratchayasakul W, Chattipakorn N, Chattipakorn SC (2012) Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci 91, 409– 414. 22925597
  86. [99]Yang Y, Ma D, Xu W, Chen F, Du T, Yue W, Shao S, Yuan G (2016) Exendin-4 reduces tau hyperphosphorylation in type 2 diabetic rats via increasing brain insulin level. Mol Cell Neurosci 70, 68– 75. 26640240
  87. [100]Xu W, Yang Y, Yuan G, Zhu W, Ma D, Hu S (2015) Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes. J Investig Med 63, 267– 272. 25479064
  88. [101]Yang Y, Ma D, Xu W, Chen F, Du T, Yue W, Shao S, Yuan G (2016) Exendin-4 reduces tau hyperphosphorylation in type 2 diabetic rats via increasing brain insulin level. Mol Cell Neurosci 70, 68– 75. 26640240
  89. [102]Candeias E, Sebastião I, Cardoso S, Carvalho C, Santos MS, Oliveira CR, Moreira PI, Duarte AI (2017) Brain GLP-1/IGF-1 signaling and autophagy mediate exendin-4 protection against apoptosis in type 2 diabetic rats. Mol Neurobiol. doi: 10.1007/s12035-017-0622-3 28573460 · DOI
  90. [103]Lannert H, Hoyer S (1998) Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 112, 1199– 1208. 9829797
  91. [104]Grünblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S (2007) Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 101, 757– 770. 17448147
  92. [105]Salkovic-Petrisic M, Osmanovic-Barilar J, Brückner MK, Hoyer S, Arendt T, Riederer P (2011) Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer’s disease: A long-term follow up study. J Neural Transm (Vienna) 118, 765– 772. 21533606
  93. [106]Correia SC, Santos RX, Santos MS, Casadesus G, Lamanna JC, Perry G, Smith MA, Moreira PI (2013) Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer’s disease. Curr Alzheimer Res 10, 406– 419. 23061885
  94. [107]Paidi RK, Nthenge-Ngumbau DN, Singh R, Kankanala T, Mehta H, Mohanakumar KP (2015) Mitochondrial deficits accompany cognitive decline following single bilateral intracerebroventricular streptozotocin. Curr Alzheimer Res 12, 785– 795. 26159195
  95. [108]Yeo HG, Lee Y, Jeon CY, Jeong KJ, Jin YB, Kang P, Kim SU, Kim JS, Huh JW, Kim YH, Sim BW, Song BS, Park YH, Hong Y, Lee SR, Chang KT (2015) Characterization of cerebral damage in a monkey model of Alzheimer’s disease induced by intracerebroventricular injection of streptozotocin. J Alzheimers Dis 46, 989– 1005. 25881906
  96. [109]Gao C, Liu Y, Jiang Y, Ding J, Li L (2014) Geniposide ameliorates learning memory deficits, reduces tau phosphorylation and decreases apoptosis via GSK3β pathway in streptozotocin-induced alzheimer rat model. Brain Pathol 24, 261– 269. 24329968 PMC8029432
  97. [110]Solmaz V, Çinar BP, Yiğittürk G, Cavuşoğlu T, Taşkiran D, Erbaş O (2015) Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats. Eur J Pharmacol 765, 482– 487. 26386291
  98. [111]Guo Z, Chen Y, Mao YF, Zheng T, Jiang Y, Yan Y, Yin X, Zhang B (2017) Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer’s rat model. Sci Rep 7, 45971. 28382978 PMC5382700
  99. [113]Moreira PI, Santos MS, Sena C, Nunes E, Seiça R, Oliveira CR (2005) CoQ10 therapy attenuates amyloid beta-peptide toxicity in brain mitochondria isolated from aged diabetic rats. Exp Neurol 196, 112– 119. 16126199
  100. [114]Carvalho C, Katz PS, Dutta S, Katakam PV, Moreira PI, Busija DW (2014) Increased susceptibility to amyloid-β toxicity in rat brain microvascular endothelial cells under hyperglycemic conditions. J Alzheimers Dis 38, 75– 83. 23948922 PMC4570500
  101. [115]Guo C, Zhang S, Li JY, Ding C, Yang ZH, Chai R, Wang X, Wang ZY (2016) Chronic hyperglycemia induced via the heterozygous knockout of Pdx1 worsens neuropathological lesion in an Alzheimer mouse model. Sci Rep 6, 29396. 27406855 PMC4942607
  102. [116]Hayashi-Park E, Ozment BN, Griffith CM, Zhang H, Patrylo PR, Rose GM (2017) Experimentally induced diabetes worsens neuropathology, but not learning and memory, in middle aged 3xTg mice. Behav Brain Res 322, 280– 287. 27173425
  103. [117]Hara Y, Yuk F, Puri R, Janssen WG, Rapp PR, Morrison JH (2014) Presynaptic mitochondrial morphology in monkey prefrontal cortex correlates with working memory and is improved with estrogen treatment. Proc Natl Acad Sci U S A 111, 486– 491. 24297907 PMC3890848
  104. [118]Peng Y, Liu J, Shi L, Tang Y, Gao D, Long J, Liu J (2016) Mitochondrial dysfunction precedes depression of AMPK/AKT signaling in insulin resistance induced by high glucose in primary cortical neurons. J Neurochem 137, 701– 713. 26926143
  105. [120]Burkewitz K, Zhang Y, Mair WB (2014) AMPK at the nexus of energetics and aging. Cell Metab 20, 10– 25. 24726383 PMC4287273
  106. [121]Sebastián D, Hernández-Alvarez MI, Segalés J, Sorianello E, Muñoz JP, Sala D, Waget A, Liesa M, Paz JC, Gopalacharyulu P, Orešič M, Pich S, Burcelin R, Palacín M, Zorzano A (2012) Mitofusin 2 (Mfn2) links mitochondrial and endoplasmic reticulum function with insulin signaling and is essential for normal glucose homeostasis. Proc Natl Acad Sci U S A 109, 5523– 5528. 22427360 PMC3325712
  107. [122]Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122, 1316– 1338. 22476197 PMC3314463
  108. [123]Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Abeta oligomers. J Clin Invest 122, 1339– 1353. 22476196 PMC3314445
  109. [124]Liu S, Okada T, Assmann A, Soto J, Liew CW, Bugger H, Shirihai OS, Abel ED, Kulkarni RN (2009) Insulin signaling regulates mitochondrial function in pancreatic beta-cells. PLoS One 4, e7983. 19956695 PMC2776992
  110. [126]Liu HY, Yehuda-Shnaidman E, Hong T, Han J, Pi J, Liu Z, Cao W (2009) Prolonged exposure to insulin suppresses mitochondrial production in primary hepatocytes. J Biol Chem 284, 14087– 14095. 19336408 PMC2682857
  111. [127]Finck BN, Kelly DP (2006) PGC-1 coactivators: Inducible regulators of energy metabolism in health and disease. J Clin Invest 116, 615– 622. 16511594 PMC1386111
  112. [128]Hardie DG (2007) AMP-activated/SNF1 protein kinases: Conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8, 774– 785. 17712357
  113. [129]Ghosh S, Patel N, Rahn D, McAllister J, Sadeghi S, Horwitz G, Berry D, Wang KX, Swerdlow RH (2007) The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cells. Mol Pharmacol 71, 1695– 1702. 17387142
  114. [130]Strum JC, Shehee R, Virley D, Richardson J, Mattie M, Selley P, Ghosh S, Nock C, Saunders A, Roses A (2007) Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis 11, 45– 51. 17361034

Cited by

Sorted by citations

Authors
Moreira, P. I.
Affiliations
Centro de Neurociências e Biologia Celular (PT)
Corresponding author
Moreira, Paula I.
ORCID
Moreira, Paula I.
Venue
Journal of Alzheimer’s Disease
Publisher
SAGE Publications
Published
2018-03-13
Volume
62
Issue
3
Pages
1391-1401
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
DOI
10.3233/jad-170931
PMC
PMC5869999
OpenAlex
W2789548786
Cited by
20
References
15
Citations by year
2024: 3 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 3
FWCI
0.39
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Programa Operacional Regional do Centro (POCI-01-0145-FEDER-007440, CENTRO-01-0145-FEDER-000012, CENTRO-01-0145-FEDER-000012-HealthyAging2020)
  • Fundação para a Ciência e a Tecnologia (01-0145, COMPETE, POCI-01-0145, PO-CI-01-0145-FEDER-007440, POCI-01-0145-FEDER-, COMPETE_2020, POCI-01-, CENTRO-01-0145-FEDER-000012 - HealthyAging2020)
  • European Regional Development Fund (COMPETE, POCI-01, POCI-01-0145-FEDER-007440, 0145-FEDER-000012, COMPETE2020, CENTRO-01-0145-FEDER-000012, POCI-01-0145- FEDER, CENTRO-01–0145-FEDER-000012-HealthyAging2020)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, diabetes mellitus
MeSH terms
Alzheimer Disease, Animals, Diabetes Mellitus, Humans, Mitochondria

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review